Abstract: . . .  leukocytes, erythrocytes or platelets. Liver function was not altered. These membrane disrupting peptide conjugates are not hemolytic, they have low antigenicity and are rapidly metabolized in vivo. These findings suggest that lytic peptide-LH/CG conjugates may be effective in treating hormone independent breast, prostate, ovarian, and testicular cancers, their metastases and disseminated cells. The concept of lytic peptide conjugate treatment provides a new mechanism for specifically destroying tumor cell membranes, without destruction of vital organs.  . . .
--657,1,328,652,3284